Is C15:0 (Pentadecanoic Acid) Safe?
Yes, pentadecanoic acid (C15:0) supplementation appears safe for human consumption based on available evidence, with no significant adverse events reported in clinical trials.
Safety Evidence from Human Studies
The most direct safety data comes from a 2024 randomized controlled trial in young adults with overweight or obesity 1. In this 12-week study, 200 mg daily C15:0 supplementation produced no significant adverse events in 20 participants. The supplement was well-tolerated, with mean increases in circulating C15:0 levels of 1.88 μg/mL compared to placebo (P = 0.003). Importantly, participants who achieved post-treatment C15:0 levels >5 μg/mL showed improvements in liver enzymes (ALT decreased by 29 U/L, P = 0.001; AST decreased by 6 U/L, P = 0.014) and hemoglobin (increased 0.60 g/dL, P = 0.010), suggesting potential health benefits rather than toxicity.
Context from Dietary Guidelines
The broader context of saturated fatty acid safety is relevant here. Current evidence does not support arbitrary upper limits on all saturated fats, as different saturated fatty acids have distinct biological effects 2. Specifically, odd-chain saturated fatty acids like C15:0 differ fundamentally from even-chain saturated fats:
- C15:0 is primarily obtained from dairy and ruminant sources, not endogenously synthesized in significant amounts
- Higher circulating C15:0 levels are associated with reduced risk of type 2 diabetes, cardiovascular disease, and mortality 3, 4
- This contrasts with even-chain saturated fats (palmitic, stearic acid) that can be endogenously synthesized and have different metabolic effects
Mechanistic Safety Profile
The molecular mechanisms of C15:0 support its safety profile 5, 6:
- No cytotoxicity detected in the BioMAP® human primary cell platform testing across 12 distinct cell systems
- Safety profile parallels metformin and rapamycin (established safe compounds) with negligible cytotoxicity
- Engages beneficial pathways: activates AMPK, inhibits mTOR, acts as dual PPARα/δ agonist
- Anti-inflammatory effects without pro-inflammatory signaling
Important Caveats
Lack of long-term safety data: While short-term (12-week) supplementation appears safe, there are no published studies examining safety beyond 3 months in humans. This represents a knowledge gap that requires acknowledgment.
Dosing considerations: The studied dose (200 mg/day) is relatively modest. Higher doses have not been systematically evaluated for safety in humans, though mechanistic studies suggest a favorable safety margin 6.
Population-specific data: Safety has only been formally tested in young adults with overweight/obesity 1. Extrapolation to other populations (elderly, pregnant women, children) requires caution pending specific studies.
Clinical Bottom Line
C15:0 supplementation at 200 mg daily is safe based on current evidence, with a favorable risk-benefit profile given the potential metabolic benefits observed. The naturally occurring presence of C15:0 in dairy products consumed for millennia provides additional reassurance. However, clinicians should inform patients about the limited long-term safety data and the need for ongoing research to establish optimal dosing and identify any rare adverse effects that may emerge with broader use.